Pfizer and Astellas Amends Clinical Research Protocols of Xtandi for 2 Phase III to treat Hormone-Sensitive Prostate Cancer (HSPC)

 Pfizer and Astellas Amends Clinical Research Protocols of Xtandi for 2 Phase III to treat Hormone-Sensitive Prostate Cancer (HSPC)

Pfizer Announces Tafamidis P-III Transthyretin Cardiomyopathy (ATTR-ACT) study results

Shots:
  • The amendments accelerate timelines for the anticipated primary completion dates of both trials
  • ARCHES and EMBARK Phase III trials have been amended its primary completion time from April 2020 to late 2018 and Mar-2021 to mid-2020 respectively
  • In Oct 2009, Pfizer (Medivation) and Astellas entered into a global agreement to jointly develop and commercialize Xtandi (enzalutamide)

Click here to read full press release/ article | Ref: Pfizer | Image:  Pfizer

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post